Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World Data
ABSTRACT Importance: The prevalence of chronic kidney disease (CKD) is increasing, with aging being a major contributor. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are well established therapies for CKD; however, adults aged 80 years or older have been underrepresented in previous large-scale trials. Consequent...